Bulk Manufacturer of Controlled Substances Application: National Center for Natural Products Research
Published Date: 11/26/2025
Notice
Summary
The National Center for Natural Products Research wants to officially make large amounts of marijuana and related substances for research and product development. If you’re a current manufacturer or interested party, you can share your thoughts or ask for a hearing by January 26, 2026. This move could boost scientific studies and product testing, with no immediate cost changes announced.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
University Seeks Bulk Schedule I Registration
The National Center for Natural Products Research applied on September 8, 2025 to be registered to bulk manufacture three Schedule I substances: Marihuana (code 7360), Marihuana Extract (code 7350), and Tetrahydrocannabinols (code 7370). The application names the center at 806 Hathorn Road, University, Mississippi 38677 and says the production is for product development and reference standards.
Stakeholders Can Comment by Jan 26, 2026
Registered bulk manufacturers of the affected drug classes and other applicants can submit electronic comments or objections, or file a written request for a hearing, on or before January 26, 2026 via https://www.regulations.gov. Upon submitting a comment you will receive a Comment Tracking Number.
Authorization Limited to Extraction From Produced Marihuana
For drug codes 7350 (Marihuana Extract) and 7370 (Tetrahydrocannabinols), the applicant plans to extract those substances from produced 7360 (Marihuana). The notice states that no other activities for these drug codes are authorized under this registration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-21189, Importer of Controlled Substances Application: Fisher Clinical Services, Inc.
Fisher Clinical Services, Inc. wants to become an official importer of certain controlled substances like marijuana and its extracts. This affects companies involved in drug manufacturing and importation, who can comment or request a hearing by December 26, 2025. No direct costs are mentioned, but the decision could impact how these substances enter the U.S. market.
Next: 2025-21191, Importer of Controlled Substances Application: Noramco
Noramco wants to become an official importer of some controlled substances like marijuana and methadone. If you’re a registered manufacturer or interested party, you have until December 26, 2025, to share your thoughts or ask for a hearing. This move could affect companies dealing with these drugs and might impact how these substances enter the U.S.